VCL Antibody

What is the optimal dilution for vinculin antibody in different experimental applications?

The optimal dilution of vinculin antibody varies significantly across different experimental applications and specific antibody products. Based on validated protocols, the following dilution ranges have been established:

For optimal results, it is essential to titrate the antibody in your specific testing system to determine the ideal concentration that maximizes signal-to-noise ratio . When working with new sample types, start with the mid-range dilution and adjust based on signal intensity and background levels.

What factors affect vinculin antibody specificity and reactivity in different tissue types?

Vinculin antibody specificity and reactivity are influenced by several factors that researchers must consider when designing experiments:

• Tissue-specific expression patterns: Vinculin is expressed in multiple tissues including myometrium, endothelial cells, retina, prostate, fetal brain cortex, uterus, platelets, and liver, but at varying levels that affect detection sensitivity .

• Antibody clone/type selection: Monoclonal antibodies (like clone VCL/2575) offer high specificity for particular epitopes, while polyclonal antibodies provide broader epitope recognition but potentially higher background .

• Fixation method impact: Formalin fixation can mask vinculin epitopes, requiring appropriate antigen retrieval methods. For IHC applications, TE buffer pH 9.0 is often recommended over citrate buffer pH 6.0 .

• Cross-reactivity potential: Antibodies raised against human vinculin may show differential reactivity with other species due to sequence homology variations. Validated reactivity has been established for human, mouse, rat, and canine samples for many vinculin antibodies .

• Isoform recognition: Some antibodies may differentially recognize vinculin (124 kDa) versus its splice variant metavinculin, depending on the immunogen region .

How should sample preparation be optimized for vinculin detection in different applications?

Proper sample preparation is crucial for successful vinculin detection across different experimental applications:

For Western Blot applications:

• Complete cell lysis is essential as vinculin is associated with the cytoskeleton

• Validated cell lysis has been performed on multiple cell lines including HEK-293, HeLa, HepG2, MDCK, NIH/3T3, and PC-12 cells

• For tissue samples, mechanical disruption followed by detergent-based lysis yields optimal results for heart tissue from both mouse and rat models

• The predicted molecular weight of vinculin is 124 kDa, with observed bands at this weight in properly prepared samples

For IHC applications:

• Paraffin-embedded tissues require appropriate antigen retrieval protocols

• For human tissue samples such as testicular carcinoma, a concentration of 2 μg/ml has been validated

• Positive staining has been confirmed in mouse colon tissue, human breast cancer tissue, human prostate cancer tissue, and human skeletal muscle tissue

• Background reduction can be achieved through proper blocking steps and antibody optimization

For IF/ICC applications:

• Cell fixation methods significantly impact epitope accessibility

• Permeabilization steps must be optimized to allow antibody access to intracellular vinculin

• Validated staining has been achieved in HepG2 and A549 cell lines

How can researchers distinguish between vinculin and metavinculin when using antibodies?

Distinguishing between vinculin and its splice variant metavinculin requires careful antibody selection and experimental design:

• Antibody selection strategy: Choose antibodies with immunogens corresponding to regions that differ between vinculin and metavinculin. For example, antibodies targeting regions outside the metavinculin-specific insert (which occurs between amino acids 883 and 884 in human vinculin) will detect both isoforms .

• Band resolution methodology: On Western blots, metavinculin appears approximately 19 kDa larger than vinculin. Using gradient gels (4-12%) and extended run times can help resolve these closely migrating proteins.

• Tissue-specific expression analysis: Metavinculin expression is primarily restricted to muscle tissues, particularly smooth, cardiac, and skeletal muscle. This tissue-specific expression pattern can be leveraged for verification of isoform specificity .

• Immunogen mapping: When selecting antibodies, carefully examine the immunogen region. For instance, antibodies like rabbit polyclonal A30448 are generated against a peptide derived from human vinculin in the region of amino acids 786-835, which is close to but does not include the metavinculin insert site .

• Validation through isoform-specific controls: Use recombinant proteins or tissues with known expression patterns of each isoform as controls to confirm antibody specificity.

What methodological approaches best resolve focal adhesion complexes using vinculin antibodies in live cell imaging?

Resolving focal adhesion complexes using vinculin antibodies in live cell imaging requires specialized techniques:

• Fluorescent protein fusion systems: Rather than direct antibody staining, generate vinculin-GFP or vinculin-mCherry fusion constructs for live cell imaging. This approach preserves the dynamic nature of focal adhesions.

• Antibody fragment adaptation: For cases requiring direct antibody detection, use Fab fragments conjugated to fluorophores rather than full IgG molecules to minimize steric hindrance within the densely packed focal adhesion complex.

• Super-resolution microscopy optimization: Techniques such as STORM, PALM, or SIM provide the necessary resolution (20-50 nm) to distinguish individual components within focal adhesions where conventional microscopy fails.

• Multi-dimensional imaging parameters:

  • Temporal resolution: Capture images at intervals of 1-5 seconds to track rapid focal adhesion dynamics

  • Spatial resolution: Use appropriate numerical aperture objectives (NA ≥ 1.4)

  • Signal-to-noise optimization: Employ deconvolution algorithms and optimal exposure settings

• Complementary marker co-visualization: Combine vinculin labeling with other focal adhesion components such as paxillin, talin, or phosphotyrosine to provide context and confirm proper focal adhesion identification.

How does phosphorylation state affect vinculin antibody binding and experimental outcomes?

Phosphorylation of vinculin significantly impacts antibody binding and experimental outcomes:

• Key phosphorylation sites affecting conformation: Vinculin contains multiple phosphorylation sites, particularly Y100, Y1065, S1033, and Y822, which can alter protein conformation and potentially mask or expose epitopes relevant to antibody binding .

• Stimulus-dependent recognition variation: Treatment of cells with agents like forskolin (40 nM for 30 minutes) has been shown to alter vinculin phosphorylation states, potentially affecting antibody recognition as demonstrated in HeLa cell lysates .

• Phospho-specific antibody considerations: When studying phosphorylation-dependent functions of vinculin, researchers should consider:

  • Using phospho-specific antibodies when available

  • Treating samples with phosphatase inhibitors during preparation

  • Comparing results from multiple antibody clones targeting different epitopes

• Experimental design modifications: For studies focusing on phosphorylation states:

  • Include both phosphatase-treated and untreated controls

  • Consider using Phos-tag™ gels to enhance mobility shifts of phosphorylated species

  • Document treatment conditions precisely, as vinculin phosphorylation is highly dynamic

• Validation approaches: Blocking experiments using synthesized peptides corresponding to phosphorylated and non-phosphorylated epitopes can help confirm specificity, as demonstrated with certain vinculin antibodies .

Why might vinculin antibody produce inconsistent staining patterns in IHC and how can this be addressed?

Inconsistent vinculin staining patterns in IHC can arise from several factors:

• Fixation variable impact: Different fixation protocols (duration, fixative type, temperature) can significantly alter epitope accessibility. For consistent results:

  • Standardize fixation time (typically 24 hours for formalin)

  • Maintain consistent fixative-to-tissue ratios

  • Process all experimental samples simultaneously when possible

• Antigen retrieval optimization: Success has been reported using both:

  • TE buffer at pH 9.0 (primary recommendation)

  • Citrate buffer at pH 6.0 (alternative approach)

  Systematic comparison of both methods with your specific tissue type is recommended.

• Antibody concentration titration: For human testicular carcinoma tissue, a concentration of 2 μg/ml has been validated , while broader recommendations suggest:

  • Starting concentration range: 1:1000-1:4000 dilution

  • Sequential dilution series testing to identify optimal concentration

  • Inclusion of both positive and negative control tissues in each experiment

• Tissue-specific considerations: Vinculin expression varies across tissues, with documented expression in:

  • Myometrium, endothelial cells, retina

  • Prostate, uterus, platelet

  • Liver and cervix carcinoma

  Unexpectedly positive tissues (e.g., mouse uterus) should be validated with alternative detection methods.

• Blocking optimization: Non-specific binding can be reduced by:

  • Extending blocking time (60 minutes minimum)

  • Using tissue-matched serum for blocking

  • Adding 0.1-0.3% Triton X-100 for improved penetration

What are the most effective validation controls for vinculin antibody specificity?

Rigorous validation of vinculin antibody specificity requires multiple complementary approaches:

• Peptide competition assays: Pre-incubation of the antibody with the immunizing peptide should abolish specific staining. This has been successfully demonstrated for several vinculin antibodies in Western blot analysis of HeLa cells and IHC of human breast carcinoma tissue .

• Multiple antibody verification: Testing multiple antibodies targeting different epitopes of vinculin should yield consistent staining patterns in validated positive controls:

  • Mouse monoclonal antibodies like VCL/2575 targeting amino acids 150-350

  • Rabbit polyclonal antibodies targeting amino acids 786-835

  • Comparison of results between antibodies can increase confidence in specificity

• Genetic manipulation controls:

  • siRNA/shRNA knockdown of vinculin should reduce signal proportionally to knockdown efficiency

  • CRISPR-Cas9 knockout cell lines provide definitive negative controls

  • Overexpression systems can verify antibody detection sensitivity

• Cross-species reactivity assessment: Determining antibody performance across species is crucial:

  • Human, mouse, rat, and canine samples have been validated for many vinculin antibodies

  • Sequence homology analysis should be performed for untested species

  • Testing must be performed empirically when working with non-validated species

• Multiple application cross-validation: Demonstration of consistent results across multiple techniques:

  • Western blot showing bands at the expected molecular weight (124 kDa)

  • IHC/IF showing expected subcellular localization patterns at cell-cell junctions and focal adhesions

  • Flow cytometry showing appropriate population distributions

How can researchers optimize multi-label immunofluorescence protocols involving vinculin antibodies?

Optimizing multi-label immunofluorescence with vinculin antibodies requires careful planning:

• Antibody selection strategy:

  • For primary antibodies: Select antibodies raised in different host species (e.g., rabbit anti-vinculin paired with mouse anti-paxillin)

  • For secondary antibodies: Choose highly cross-adsorbed versions to minimize cross-reactivity

  • Validate each antibody individually before attempting co-labeling

• Sequential staining protocol optimization:

  • Order matters: Begin with the lowest abundance target protein

  • When using rabbit polyclonal anti-vinculin antibodies (like A30448), apply at 1:100-1:300 dilution

  • For mouse monoclonal antibodies like VCL/2575, 2 μg/ml concentration has been validated

  • Include thorough washing steps (3-5 washes) between primary antibodies

• Fluorophore selection to minimize spectral overlap:

  • Choose fluorophores with well-separated excitation/emission spectra

  • Consider brightness hierarchy: match brightest fluorophores to lowest abundance proteins

  • Perform single-label controls to establish bleed-through parameters

• Image acquisition parameters:

  • Capture each channel separately rather than simultaneously

  • Use sequential scanning for confocal microscopy

  • Maintain consistent exposure settings across experimental conditions

  • Include unstained and single-stained controls for each experiment

• Advanced troubleshooting for co-localization studies:

  • For unclear results, perform proximity ligation assays (PLA) to confirm protein-protein interactions

  • Use super-resolution techniques for definitive co-localization analysis

  • Apply appropriate co-localization statistical analysis (Pearson's correlation coefficient or Manders' overlap coefficient)

What role do anti-vinculin antibodies play in autoimmune and inflammatory conditions?

Anti-vinculin antibodies have emerged as important biomarkers in several autoimmune and inflammatory conditions:

• Inflammatory bowel disease (IBD) connection:

  • Anti-vinculin antibodies are elevated in some IBD patients, particularly those with irritable bowel syndrome with diarrhea (IBS-D)

  • Detection methods include specialized ELISA kits with sensitivity of < 0.938 ng/ml and detection range of 1.563-100 ng/ml

  • These antibodies may serve as biomarkers distinguishing IBD from functional gastrointestinal disorders

• Rheumatoid arthritis implications:

  • Vinculin, as a cytoskeletal protein involved in mechanosensing, becomes exposed during tissue damage

  • Anti-vinculin antibodies may contribute to perpetuating inflammation at joints

  • Testing for these antibodies requires specialized sandwich ELISA techniques

• Mechanistic pathways in autoimmunity:

  • Molecular mimicry between microbial antigens and vinculin may trigger autoantibody production

  • Disruption of barrier integrity (gut, vascular) may expose vinculin to immune system

  • These antibodies may interfere with normal cellular adhesion and migration functions

• Diagnostic considerations:

  • Quantification methods must be standardized (ELISA recommended over Western blot)

  • Reference ranges need to be established for different patient populations

  • Combined testing with other autoantibodies improves diagnostic accuracy

• Therapeutic implications:

  • Monitoring anti-vinculin antibody levels may help assess treatment efficacy

  • Targeted immunoadsorption techniques may be developed to remove pathogenic antibodies

  • Understanding epitope specificity could inform targeted therapy development

How can vinculin antibodies be utilized to study cancer cell invasion and metastasis?

Vinculin antibodies provide valuable tools for investigating cancer cell invasion and metastasis:

• Focal adhesion dynamics in cancer progression:

  • Vinculin localization and expression changes correlate with invasive potential

  • Using vinculin antibodies for immunofluorescence (1:200-1:800 dilution) enables visualization of focal adhesion structure and turnover in:

    • Human glioblastoma-astrocytoma (U-87)

    • Human monocytic leukemia (THP-1)

    • Human breast carcinoma cells

• Quantitative assessment methodologies:

  • Western blot analysis (1:5000-1:60000 dilution) allows quantification of total vinculin expression

  • Flow cytometry (0.20 μg per 10^6 cells) enables single-cell analysis of vinculin expression heterogeneity within tumor populations

  • IHC (1:1000-1:4000 dilution) permits analysis of vinculin expression in primary tumor tissues and metastatic sites

• Experimental models optimized for vinculin study:

  • 2D migration assays: Vinculin antibody staining reveals focal adhesion distribution at leading edges

  • 3D invasion assays: Differential vinculin localization can be assessed in matrix-embedded cells

  • Orthotopic xenograft models: IHC analysis of tumor sections can correlate vinculin expression patterns with invasive fronts

• Mechanotransduction investigation approaches:

  • Vinculin's role in sensing matrix stiffness can be studied using antibodies on cells cultured on substrates of varying rigidity

  • Co-staining with phosphorylation-specific antibodies can reveal activation states related to mechanosensing

  • Live-cell imaging combined with vinculin biosensors enables real-time assessment of mechanical forces during invasion

• Correlation with clinical outcomes:

  • IHC analysis of vinculin in human tumor samples from various tissues including:

    • Testicular carcinoma

    • Breast carcinoma

    • Prostate cancer

  • These analyses can be correlated with staging, patient survival, and response to therapy

How can advanced microscopy techniques enhance vinculin-based research?

Advanced microscopy techniques significantly enhance the resolution and information obtained from vinculin-based research:

• Super-resolution microscopy applications:

  • Techniques such as STORM, PALM, and SIM overcome the diffraction limit, enabling visualization of individual focal adhesions at nanoscale resolution

  • Recommended vinculin antibody dilutions for super-resolution: Start with standard IF dilutions (1:200-1:800) and optimize based on signal density

  • These approaches reveal previously undetectable substructures within vinculin-containing adhesion complexes

• FRET-based tension sensor integration:

  • Combining vinculin antibody staining with FRET-based tension sensors allows correlation between force transmission and vinculin recruitment

  • This approach requires specialized vinculin constructs with inserted FRET sensor modules

  • Complementary immunostaining with vinculin antibodies can validate FRET sensor distribution and expression levels

• Live-cell imaging optimization for dynamic studies:

  • For fixed timepoint analyses, conventional antibody staining provides high signal quality

  • For live dynamics, fluorescent protein fusions or nanobody-based detection systems offer alternatives to traditional antibodies

  • Correlative light-electron microscopy (CLEM) combines the specificity of vinculin immunofluorescence with ultrastructural context

• Multiplexed imaging approaches:

  • Cyclic immunofluorescence (CycIF) or imaging mass cytometry allows detection of dozens of proteins in the same sample

  • These methods require validation of vinculin antibody compatibility with the multiplexing protocol

  • Start with validated antibodies in single-staining conditions before incorporating into multiplexed workflows

• Quantitative image analysis recommendations:

  • Automated focal adhesion detection and measurement based on vinculin staining

  • Machine learning algorithms for pattern recognition in complex vinculin distribution

  • 3D reconstruction of vinculin-containing structures in thick tissue sections or organoids

What are the best protocols for studying vinculin phosphorylation and its functional consequences?

Studying vinculin phosphorylation requires specialized approaches beyond standard antibody applications:

• Phosphorylation site-specific detection strategies:

  • Use of phospho-specific antibodies targeting known sites (Y100, Y1065, S1033, Y822)

  • Phos-tag™ SDS-PAGE followed by standard vinculin antibody detection (1:5000-1:60000 dilution)

  • Mass spectrometry analysis for unbiased phosphorylation site mapping

• Sample preparation to preserve phosphorylation status:

  • Immediate cell lysis in buffers containing phosphatase inhibitors

  • Flash freezing of tissue samples prior to processing

  • Treatment of cells with phosphatase inhibitors (e.g., okadaic acid, calyculin A) to enhance phosphorylation detection

• Functional correlation experimental designs:

  • Site-directed mutagenesis (phospho-mimetic and phospho-deficient) combined with antibody validation

  • Kinase inhibitor treatments followed by vinculin phosphorylation assessment

  • Correlation of phosphorylation status with mechanical properties via traction force microscopy

• Stimulation protocols for dynamic phosphorylation studies:

  • Forskolin treatment (40 nM, 30 minutes) has been validated to alter vinculin phosphorylation state

  • Mechanical stimulation (stretch, fluid shear) protocols to trigger mechanosensitive phosphorylation

  • Growth factor stimulation timepoints (5, 15, 30, 60 minutes) to capture temporal dynamics

• Validation controls and troubleshooting:

  • Lambda phosphatase treatment as negative control

  • Comparison of results using multiple vinculin antibodies targeting different epitopes

  • Blocking peptide experiments with phosphorylated and non-phosphorylated peptides to confirm specificity

How can researchers effectively integrate vinculin studies with other cytoskeletal and adhesion markers?

Integrating vinculin studies with other cytoskeletal and adhesion markers requires careful experimental design:

• Co-immunoprecipitation optimization with vinculin antibodies:

  • Use of antibodies suitable for immunoprecipitation (typically requiring higher affinity)

  • Gentle lysis conditions to preserve protein-protein interactions

  • Crosslinking approaches to capture transient interactions

  • Western blot confirmation using vinculin antibodies at 1:5000-1:60000 dilution

• Multi-protein localization strategies:

  • Sequential staining protocols with vinculin antibodies (1:200-1:800) and other markers

  • Selection of complementary fluorophores with minimal spectral overlap

  • Use of primary antibodies from different host species to avoid cross-reactivity

  • Confocal microscopy with appropriate controls for bleed-through

• Functional perturbation experimental designs:

  • siRNA knockdown of vinculin followed by assessment of other adhesion proteins

  • Pharmacological disruption of specific cytoskeletal elements combined with vinculin immunostaining

  • CRISPR-Cas9 genome editing of vinculin or partner proteins with antibody validation

• Contextual tissue architecture analysis:

  • IHC of tissue sections (1:1000-1:4000 dilution) to reveal vinculin in tissue context

  • Multiplex immunofluorescence for simultaneous detection of vinculin and ECM components

  • 3D reconstruction from serial sections to understand spatial relationships

• Quantitative co-localization analysis approaches:

  • Pearson's correlation coefficient for degree of overlap

  • Manders' overlap coefficient for proportional overlap

  • Object-based co-localization for discrete adhesion structures

  • Time-resolved co-recruitment analysis for dynamic studies